StockIQpro
NASDAQ:OCUL

Ocular Therapeutix, Inc.

Track all markets on TradingView
Track all markets on TradingView

Ocular Therapeutix, Inc.'s revenue fell 18.5% in fiscal 2025 to $52.0M while operating margin fell to −519.8%. Free cash flow was −$216.9M, −417.5% of revenue, and the diluted share count rose 18.3%.Summary generated from Ocular Therapeutix, Inc.'s SEC filings. Latest annual report filed Feb 5, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$52.0M
Revenue growth−18.5%
Revenue, 5-yr CAGR+24.4%
Gross margin87.3%
Operating margin−519.8%
Net margin−511.9%
ROICn/a
Return on equity−54.9%
Debt / equityn/a
Free cash flow−$216.9M
FCF margin−417.5%
Share count change+18.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue4451586452
Operating income−78−79−82−172−270
Net income−7−71−81−194−266
Free cash flow−67−63−76−136−217

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations